promising activity of neoadjuvant #CDKi plus #giredestrant in ERpos/HER2neg #breastcancer (coopERA Breast Cancer) thelancet.com/journals/lanon…

Julie Hallet Society of Surgical Oncology Patricio Polanco IHPBA Zhi Ven Fong, MD MPH DrPH Giovanni Marchegiani Ajay Maker Flavio G Rocha, MD, FACS, FSSO Callisia Clarke MD Melissa Hogg Miral Sadaria Grandhi ☺️👍 PREOPANC2 by DPCG Bas Groot Koerkamp thelancet.com/journals/lanon…

~2 wks to #ESMO25! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter ESMO - Eur. Oncology OncoAlert

3/ Key findings from the survey: 🔹 Patients with pre-existing neuropathy 🔹 Those with predominant non-urothelial histology 🔹 Poor performance status 🔹 Or really uncontrolled diabetes (HbA1c > 11%) might not be the best candidates for EV-P due to higher risk of toxicity or

4/ Importantly, all these profiles would have been excluded from the pivotal EV-302 and EV-301 trials, yet they are common in real-world practice. The next challenge is to generate evidence in this high-risk population and explore novel therapeutic options or molecularly driven

An interesting venue (Cancer Cell!) for this randomized phase 3 trial in #PancreaticCancer. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer cell.com/cancer-cell/fu… Sequential NAT v upfront surgery in resectable PDAC!

💊 Steroids save lives in oncology but quietly break bones 🦴 From chemo pre-meds to IO toxicity, glucocorticoids are everywhere. But even “low-dose” steroids can silently cause osteoporosis & fractures within months ⚠️ 📉 Why it matters? • 5× ↑ vertebral fracture risk with

The NAT arm was associated with better overall survival vs upfront surgery arm (35.4 months vs 27.2 months, HR 0.7, p=0.04). Notably, 83.3% of NAT pts made it to resection, with 78.4% completing all intended cycles. 76.5% upfront surg pts got chemo, 53.7% completing all cycles.

That said, for the upfront surgery group, 75.4% received gem/cape, only 8.8% receiving mFFX. I’m not sure if it’s a fair comparison if one group mostly received gem/cape and the other both gem/abraxane and mFFX. But that goes against my personal bias so I’m ignoring it. End🧵

#ESMO25 OS with first- vs second-line CDK4/6i in HR+/HER2– ABC (SONIA trial) 🔹 mFU 58.5 mo 🔹 OS: 47.9 mo (1L) vs 48.1 mo (2L) 🔹 Trend favoring 1L only in premenopausal pts (HR 0.53) 💬 No significant OS difference — similar outcomes, more toxicity & cost with 1L CDK4/6i?

#TumorBoardTuesday 📊Who feels overwhelmed🌊by all the potential uses of ctDNA🧬testing in colon cancer🙋 📢Well then join us Tuesday, 10-14-25 at 8PM ET as Aparna Raj Parikh & Emerik Osterlund🗣️the use of ctDNA in CRC RT and bring others into the discussion‼️

#ESMO25 BEGONIA: Dato-DXd + Durvalumab as 1L in a/mTNBC 🔹 All-comer cohort: ORR 79%, mDoR 17.6 mo, mPFS 14 mo 🔹 PD-L1–high cohort: ORR 82% 💬 In line with ASCENT-03/04 and TROPION-Breast02, supporting chemo-free ADC+/-IO as a potential new 1L strategy in mTNBC

Very interesting preliminary data to support the use of oral #SERD (in this case #giredestrant) without ovarian function suppression in premenopausal women with HR+/HER2- early #BreastCancer OncoAlert ESMO - Eur. Oncology #ESMO25 Ann Partridge MD, MPH

#ESMO25 BEGONIA update : Dato-DXd + Durvalumab in 1L a/mTNBC 🔹 All-comer cohort: ORR 79%, mDoR 17.6 mo, mPFS 14 mo 🔹 PD-L1–high cohort: ORR 82% 💬 Alongside ASCENT-04/03 and TROPION-Breast02, supports ADC±IO as a rising 1L option in TNBC.

Huge congrats to Tom Powles on shifting the paradigm in #bladdercancer (& frankly #cancer at large) w #IMvigor011, paving the way ctDNA as a tool for potentially allocating #adjuvant therapy. Bravo also on the simultaneous NEJM publication!

A standing ovation moment at #ESMO25 In front of more than 9,000 cancer specialists and researchers, the Phase 3 RC48-C016 trial redefined the outlook for HER2-expressing urothelial cancer: Disitamab vedotin + Toripalimab nearly doubled overall survival over chemotherapy —

Saturnsky, MBA, BigTech Exec Corporate Demon About 10–20% of urothelial carcinomas show HER2 overexpression or amplification, depending on the assay and cutoff used (IHC ≥ 1+ or gene amplification). That molecular subset is now emerging as a therapeutically actionable group — much like in breast and gastric cancers.

Every young oncologist interested in improving oral presentation skills should watch Tom Powles masterful presidential delivery of IMvigor011. The slides alone do not to his art of communication enough justice... You will need #ESMO25 access for this one.

My ecancer #ESMO25 highlights video is now live! Watch for an unbiased commentary on the most important trials and studies from ESMO Annual Meeting. This 35 minute video will give you the best of ESMO plus critical appraisal and minus the hype. ecancer.org/en/video/12543…

🎗️ OncoWisdom Circle & Fortis Cancer Institute, Mumbai present “How to Make Sense of Breast Cancer Data from ESMO 2025” 🗓️ 5 November 2025 | 7:00 PM IST 📍 Online | Free Registration A focused, high-yield academic session that cuts through the noise — and makes real-world sense